IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Headaches are a common medical problem that physicians frequently encounter in their
 practice. One of key findings of The Atlas of Headache Disorders prepared by World Health
 Organization (WHO) is: headache disorders, including migraine and tension-type headache
 (TTH), are among the most prevalent disorders of mankind. The fixed combination of
 indomethacin, prochlorperazine and caffeine (IndoProCaf) showed efficacy and safety in acute
 treatment of migraine and episodic tension-type headache attacks. IndoProCaf (Difmetre®) is
 widely used in common daily practice only in Italy from early 1970s, is available at the
 Commonwealth of Independent States (CIS) pharmaceutical market now. There are limited data
 regarding IndoProCaf usage from post-marketing settings. This will be a first post-marketing
 observational study which aimed to evaluate the effectiveness and patients' satisfaction of
 primary headaches acute treatment in routine clinical settings in Ukraine and Kazakhstan.
The study is designed as a prospective, multicentre, observational, non-interventional,
 non-randomized, non-controlled, single arm, post-marketing study where IndoProCaf will be
 prescribed in the usual manner per standard clinical practice of the treating physician and
 in accordance with the terms of the locally approved instruction for medical use. No
 additional procedures (other than the standard of care) shall be applied to the patients.
Inclusion Criteria:

 -  Diagnosis of primary headache (migraine with or without aura and/or episodic TTH) and
 whose headache attacks required acute pharmacological treatment.

 -  Were administered IndoProCaf (Difmetre®) effervescent tablets therapy according to the
 local product labelling.

 -  Adults 18 years and older (male, female).

 -  Provide Authorization to the investigator to use and/or disclose personal and/or
 health data.

 Exclusion Criteria:

 -  Meet contraindications for treatment with IndoProCaf (Difmetre®) effervescent tablets
 as outlined in the latest version of local product labelling.

 -  Patients who are required prescription by physician of IndoProCaf and nonsteroidal
 anti-inflammatory drug-containing products at the same time for acute headache attacks
 treatment.

 -  Previous discontinuation of IndoProCaf treatment due to safety (i.e. hypersensitivity)
 events, lack of efficacy.

 -  Female patients who are pregnant or are breast-feeding.